Ebba Fåhraeus
Elected 2018
Born: 1963.
Education: MBA from the Stockholm School of Economics, Sweden.
Experience and previous assignments: Ebba Fåhraeus has deep and wide experience in business development, growth strategies and marketing in both listed and non-listed life sciences companies.
Other current assignments: CEO of SmiLe Incubator in Lund, member of the boards of the Faculty of Medicine at Lund University, Carasent ASA, Skandia’s General Assembly, Coala Life and member of the Government Office’s advisory group for life science.
Total holdings in AcuCort: 496,620 shares.
Independent in relation to the company and its management and in relation to major shareholders.
Anna Eriksrud
Elected 2017
Born: 1958
Education: International MBA from Uppsala University, Sweden.
Experience and previous assignments: Anna Eriksrud has a background as a health care entrepreneur with over 25 years of experience in the medical and pharmaceutical sector, primarily from Q-Med and Pharmacia. She has run her own business through Apoteksamariten and has leadership experience from international cross-functional teams, establishing new market categories and launching global brands both in Europe and the US.
Other current assignments: CEO of NeoDynamics AB.
Total holdings in AcuCort: 80,877 shares.
Independent in relation to the company and its management and in relation to major shareholders.
Göran Tornling
Elected 2021
Born: 1947
Education: M.D., Ph.D., Professor Emeritus in pulmonary medicine at Karolinska Institutet, Stockholm, Sweden.
Experience and previous assignments: Göran Tornling has more than 20 years of experience from all phases of clinical development in the pharmaceutical industry and he has held leading positions at AstraZeneca, Orexo and a number of smaller life science companies.
Other current assignments: Chief Medical Officer at Gesynta Pharma AB and Senior Advisor at Vicore Pharma AB.
Total holdings in AcuCort: 104,160 shares.
Independent in relation to the company and its management and in relation to major shareholders.
Helen Ljungdahl Round
Elected to the Board 2025
Year of Birth: 1964
Education: Bachelor’s degree in Economics from Uppsala University and an MBA from the American Graduate School of International Management (Thunderbird), AZ, USA.
Experience and previous assignments: Helen Ljungdahl Round has extensive, international experience in Life Science, spanning from pre-clinical biotech start-ups to publicly listed MedTech companies, with a focus on growth in the U.S. market. Through her executive roles, Helen has gained significant expertise in business development, international product launches, and forming strategic partnerships. She has a deep understanding of the challenges companies face when launching products in the U.S. market. Helen also has experience in board work.
Other current assignments: Advisor to SonicCloud, USA
Total holdings in AcuCort: –
Independent in relation to the company and management and in relation to major shareholders.
Jan Poulsen
Elected to the Board 2025
Experience and previous assignments: Jan Poulsen has extensive experience as CEO, leading and developing companies and driving growth across multiple industries and EU countries. He has more than 25 years of investment experience in the biotech and medtech sectors and is involved in several companies focused on expansion and growth in the U.S. market. Jan also has board experience and contributes with a broad investor network and relevant industry knowledge.
Jonas Jönmark
CEO since 2020
Born: 1971
Education: MBA from Lund University, Sweden.
Experience and prior assignments: Jonas Jönmark has more than 20 years of experience from leading positions as well as the CEO role in the pharmaceutical industry and the life science sector. His career has included big international pharma companies such as Pfizer, Astellas Pharma and Astra Zeneca, but also smaller start-up companies such as LifeScience Support and Alteco Medical. His track record includes broad experience from international business development, global product launches and creating strong sales growth.
Other current assignments: None.
Total holdings in AcuCort: 362,327 shares.